Treatment of Celiac Disease in Refractory Coeliac Disease Type 2 (RCD-II) with Aberrant Intraepithelial Lymphocytes

Not all patients with celiac disease recover on a gluten-free diet. When specific immunophenotypic changes in the small bowel persist after at least 12 months of strict dietary adherence, the condition meets criteria for Refractory Coeliac Disease Type 2 — a distinct subtype requiring a targeted management approach.

Clinical Scenario

RCD-II

The defining feature of this subtype is an aberrant intraepithelial lymphocyte (IEL) population in the small bowel. These lymphocytes show loss of surface CD3 and CD8 with retained intracytoplasmic CD3 expression. Flow cytometry typically demonstrates ≥ 20% aberrant IELs, and clonality is confirmed by T-cell receptor (TCR) gene rearrangement analysis. This phenotype arises in the context of at least 12 months on a strict gluten-free diet (GFD).

Treatment Approach

For mild-to-moderate RCD-II, the protocol is built around a specific targeted corticosteroid, with nutritional support incorporated where clinically indicated. Severely ill patients are managed along a different pathway.

Full regimen, dosing schedule, and algorithm available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/ueg2.70195

RCD‑II: Is defined by the presence of an aberrant IEL population characterised by loss of surface CD3 and CD8, with expression of intracytoplasmic CD3.
Flow cytometry typically demonstrates ≥ 20% aberrant IELs, and clonality is confirmed by T‑cell receptor (TCR) gene rearrangement analysis.
Mild‑to‑moderate RCD‑II may be treated with open‑capsule budesonide.
Seriously ill patients might require alternative treatment including parenteral steroids.

View source ↗